Q-omics provides the consensus-scored RBM38 profile across patient tissues and cancer cell-line models. RBM38 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM38 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, RBM38 RNA expression shows 18,209 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where RBM38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM38 survival associations across molecular data types. RBM38 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM38 RNA expression–survival associations across cancer types. High RBM38 expression shows unfavorable associations in ACC, KIRC, LGG and LIHC, but favorable associations in CESC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM38 RNA expression.
This table summarizes RBM38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM38 shows lower tumor expression in BLCA and KICH and higher tumor expression in LIHC, HNSC, CHOL and LUSC. The LIHC box plot shows higher RBM38 RNA expression in tumor versus normal tissue (log2 FC = +0.870, t-test p < 0.001).
This table shows molecular features associated with RBM38 in patient tissues and cancer cell lines. In patient samples, RBM38 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
